First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424

First Patient Advanced Prostate Cancer Treated with Harpoon Therapeutics’ HPN424
A Phase 1 clinical trial of Harpoon Therapeutics’ immunotherapy candidate, HPN424 for metastatic castration-resistant prostate cancer (mCRPC), has treated the first patient, according to the company. HPN424 uses the Harpoon’s TriTAC (Tri-specific T cell Activating Construct) platform. This approach is intended to work as an adaptor, connecting the patient’s own immune T-cells with tumor cells. This is possible because TriTAC products target cancer cells and immune cells at the same time, bringing them together. HPN424, particularly
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *